Expert consensus on combination therapies of oral anti-diabetic drugs for adults with type 2 diabetes (2025 edition).
10.3760/cma.j.cn112138-20250515-00279
- Collective Name:Chinese Endocrinologist Association
- Publication Type:Consensus Development Conference
- MeSH:
Humans;
Diabetes Mellitus, Type 2/drug therapy*;
Hypoglycemic Agents/administration & dosage*;
Drug Therapy, Combination;
Administration, Oral;
Consensus;
Adult
- From:
Chinese Journal of Internal Medicine
2025;64(8):707-722
- CountryChina
- Language:Chinese
-
Abstract:
Combination therapies involving oral anti-diabetic agents with complementary mechanisms of action are widely employed in the clinical management of type 2 diabetes mellitus (T2DM). Initiating combination therapy early-either at diagnosis or through timely escalation from monotherapy-can expedite achievement of individualized glycemic targets and slow disease progression in newly diagnosed patients. The inclusion of agents with weight-reducing properties is particularly beneficial for overweight or obese individuals, as it enhances insulin sensitivity and facilitates glycemic control. Moreover, selecting combinations with proven cardiovascular and renal benefits offers long-term organ protection and improves overall prognosis. This consensus statement provides guidance on the optimal use of oral combination therapies for effective and individualized management of T2DM in clinical practice.
